Article Details
Retrieved on: 2024-09-03 17:51:25
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a gene therapy, RGX-121, developed by RegenxBio to treat Hunter syndrome (MPS II), highlighting its positive trial results and future clinical endpoints. It relates to biotech through tags such as gene therapy, Mucopolysaccharidosis, and clinical endpoints.
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here